These findings not only indicate a novel mechanism by which AF hampers cardiomyocyte function, but also propose PARP1-inhibition and/or NAD+ supplementation as a possible therapeutic target that may preserve the proteostasis network and cardiomyocyte function in clinical AF. The gene discussed is PARP1; the disease is atrial fibrillation.